ID: ALA5219688

Max Phase: Preclinical

Molecular Formula: C17H19N3O3S2

Molecular Weight: 377.49

Representations

Canonical SMILES:  Cc1ncc(S(=O)(=O)NC(=O)Nc2c3c(cc4c2CCC4)CCC3)s1

Standard InChI:  InChI=1S/C17H19N3O3S2/c1-10-18-9-15(24-10)25(22,23)20-17(21)19-16-13-6-2-4-11(13)8-12-5-3-7-14(12)16/h8-9H,2-7H2,1H3,(H2,19,20,21)

Standard InChI Key:  JCFFSDANQNWAIV-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 377.49

Molecular Weight (Monoisotopic): 377.0868

AlogP: 2.94

#Rotatable Bonds: 3

Polar Surface Area: 88.16

Molecular Species: ACID

HBA: 5

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 6

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 5.14

CX Basic pKa: 0.56

CX LogP: 3.44

CX LogD: 2.51

Aromatic Rings: 2

Heavy Atoms: 25

QED Weighted: 0.86

Np Likeness Score: -1.01

References

1. McBride C, Trzoss L, Povero D, Lazic M, Ambrus-Aikelin G, Santini A, Pranadinata R, Bain G, Stansfield R, Stafford JA, Veal J, Takahashi R, Ly J, Chen S, Liu L, Nespi M, Blake R, Katewa A, Kleinheinz T, Sujatha-Bhaskar S, Ramamoorthi N, Sims J, McKenzie B, Chen M, Ultsch M, Johnson M, Murray J, Ciferri C, Staben ST, Townsend MJ, Stivala CE..  (2022)  Overcoming Preclinical Safety Obstacles to Discover (S)-N-((1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl)-6-(methylamino)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide (GDC-2394): A Potent and Selective NLRP3 Inhibitor.,  65  (21.0): [PMID:36279149] [10.1021/acs.jmedchem.2c01250]

Source

Source(1):

• Scientific Literature